TOP 10 PHARMACEUTICAL COMPANIES BY REVENUES:
JOHNSON AND JOHNSON: $82.1 billion
ROCHE: $63.3 billion
PFIZER: $51.75 billion
NOVARTIS: $47.45 billion
MERCK: $46.84 billion
GSK: $ 43.92 billion
SANOFI: $39.28 billion
ABBVIE: $33.27 billion
ABBOTT: $31.90 billion
TAKEDA: 31.17 billion
Other major pharma companies are:
BMS: $26.15 billion
AMGEN: $21.30 billion
NOVO NORDISK: $18.30 billion
Janssen reported the annual revenues of $82.1 billion, pharmaceutical segment contributed to $ 42.20 billions
The group has reported growth of 0.6%. The pharmaceutical division reported growth of 3.6%. The growth has been driven by Stelara (ustekinumab), Darzalex (daratumumab), Imbruvica (ibrutinib), Tremfya (guselkumab), Invega Sustenna/Xeplion/Invega Trinza/Trevicta (paliperidone palmitate) . The sales of Remicade declined because of biosimilars.
Roche presented impressive financial data, group sales rose by 9%, reported net sales of USD 63.3 bn
Roche sales were increased by 9%. The group has reported USD 63.30 bn
The revenues of the pharmaceutical division was CHF 48.5 bn (50.03 bn)
The company reported an increase in sales by 13% in the USA, Japan by 9% and international sales by 15%
Avastin sales were increased by 4%
Rituxan/Mabthera sales in Europe and Japan were affected by biosimilar competition. In Europe, sales were decreased by 33% and 44% in Japan
Ocrevus sales were increased by 57%; the company reported sales of CHF 3.7 bn (USD 3.82 bn)
Pfizer has reported a decline in sales by 4%; reported annual sales of USD 51.75 bn
The revenues were dropped by 4%
Eliquis sales were increased by 23%; the company has reported sales of USD 4.22 bn
Ibrance sales were increased by 20%. The company has reported revenues of USD 4.96 bn
A mere 1 % boosted Prevnar 13 sales, sales of USD 5.85 bn was reported
Lyrica revenues were USD 3.32 bn and of Lipitor were USD 1.97 bn
Xeljanz reported sales of 2.24 bn and Pfizer share of Enbrel was 1.70 bn
Novartis presented strong financial data supported by Cosentyx and Entresto; sales increased by 9%; reported net sales USD 47.45 bn
Novartis announced that full-year net sales rose by 9%. The company has reported net sales of USD 47.45 bn
The results were mostly driven by sales of Cosentyx (USD 3.6 bn, increased by 28%), Entresto (USD 1.7 bn, increased by 71%) and Zolgensma
The company has reported sales of USD 37.7 from innovative medicines. Sandoz has reported sales of USD 9.7 bn
The company’s last year best selling product Gilenya sales were reduced by 4%. The net sales of Gilenya were USD 3.22 bn. The company reported that the sales decreased because of the competition
Xolair sales were increased by 13%. The company reported sales of USD 1.17 bn
Merck reported sales of $46.8 billion, an increase of 11%, Keytruda sales were increased by 55%
Merck has reported increase in sales by 11%. The sales were primarily driven by Keytruda.
The company reported the sales of Keytruda as more than $ 11 billion, compared to $ 7 billion in 2018
Gardasil/ Gardasil 9 revenues were $ 3.74 billion
ProQuad / M-M-R II / Varivax were reported as $ 2.23 billion
Our startup needs your support. Please donate to support iPharmaCenter. Click on donate in the header to support us.
Thank you!
For pipeline, market overview, SLRs, and market access reports (syndicate and customised) please write to sales@firstviewinsight.com
For all syndicate reports: Click here